Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A chemoproteomic map of compound candidate to arrest cell growth in pancreatic cancer patient-derived organoids

ABSTRACT: We here present a proteomic study of drug inhibiting the cell growth of pancreatic cancer patient-derived organoids

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Ka Yang

LAB HEAD: Junmin Peng

PROVIDER: PXD031663 | Pride | 2024-05-27

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	Chen_PDAC_f01.1.pepXML	Pepxml
	Chen_PDAC_f01.raw	Raw
	Chen_PDAC_f02.1.pepXML	Pepxml
	Chen_PDAC_f02.raw	Raw
	Chen_PDAC_f03.1.pepXML	Pepxml

Items per page:

1 - 5 of 193

Similar Datasets

Evaluation of a Pooling Chemoproteomics Strategy with an FDA-approved Drug Library

Project description:Chemoproteomics is a key platform for characterizing the mode of action (MoA) for compounds, especially for targeted protein degraders such as proteolysis targeting chimerics (PROTACs) and molecular glues. With deep proteome coverage, multiplexed tandem mass tag-mass spectrometry (TMT-MS) can tackle up to 18 samples in a single experiment. Here, we present a pooling strategy to further enhance the throughput, and apply the strategy to an FDA-approved drug library (95 best-in-class compounds). The TMT-MS-based pooling strategy was evaluated in the following steps. First, we demonstrated the capability of TMT-MS by analyzing over 15,000 unique proteins (>12,000 gene products) in HEK293 cells treated with five PROTACs (two BRD/BET degraders and three degraders for FAK, ALK, and BTK kinases). We then introduced a rationalized pooling strategy to separate structurally similar compounds in different pools, and identified the proteomic response to 14 pools from the drug library. Finally, we validated the proteomic response from one pool by re-profiling the cells under individual drug treatment with sufficient replicates. Interestingly, numerous proteins were found to change upon drug treatment, including AMD1, ODC1, PRKX, PRKY, EXO1, AEN and LRRC58 by 7-Hydroxystaurosporine; C6orf64, HMGCR and RRM2 by Sorafenib; SYS1 and ALAS1 by Venetoclax; and ATF3, CLK1 and CLK4 by Palbocilib. Thus, the pooling chemoproteomics screening provides an efficient method for dissecting the molecular targets of compound libraries.

2023-03-11 | PXD033780 | Pride

large scale brain proteome profiling of 3xtg mice

Project description:A large scale profiling of 3xtg mouse brain to invetigate the AD proteomic phenotype.

2024-06-25 | PXD053314 | Pride

Proteome-wide pulse labeling reveals amyloid-impaired protein degradation in Alzheimer’s disease

Project description:We here present a large-scale proteome-wide profiling of protein turnover in Alzheimer's disease mice model. We integrated in vivo pulse-SILAC labeling and TMT multiplexing with novel mass spectrometry to precisely measure protein half-lives.

2024-10-28 | PXD031830 | Pride

Ubiquitinome of G401 SMARCB1-deficient rhabdoid tumor cells

Project description:In this study, DCAF5, a substrate receptor that has been shown to modulate the levels of SWI/SNF subunits, which are components of a chromatin remodeling complex. Here we preformed ubiquitinome proteomics to discover the underlying response of DCAF5 loss on ubiquitylation of SWI/SNF subunits. Furthermore, we determine what sites on SWI/SNF components decrease in ubiquitylation upon DCAF5 loss.

2024-03-25 | PXD046463 | Pride

Induction of muscle atrophy by tumor and dexamethasone regulates a distinct set of proteins from atrophy caused by aging

Project description:To assess changes in the muscle proteome that due to tumor burden and dexamethasone treatments and compare proteomic changes that occur in atrophy due to tumor burden and dexamethasone treatment with atrophy caused by aging. Regulators of muscle atrophy induced by diseases such as cancer or drugs such as dexamethasone are largely unknown. We would therefore like to determine the proteomic signature of atrophying muscle caused by tumor burden (LLC cell injected mice) and dexamethasone treatment in order to examine possible biomarkers and regulators of muscle atrophy. We would also like to compared the proteomic signature of different modes of muscle atrophy to determine similarities and differences in the possible biomarkers and regulators.

2022-02-22 | PXD027490 | Pride

ATM-knockout on total and phosphorylation proteomes of cortical brain organoids

Project description:ATM (ataxia telangiectasia mutated) kinase is crucial to a wide range of human developmental disorders and adult/pediatric malignancies. Its mutations are causally tied to ataxia telangiectasia, a multi-systemic congenital disorder mainly affecting brain and blood systems. We generated 4 separate ATM-knockout human pluripotent stem cell lines and differentiated them to form 3-dimensional brain cortical brain organoids. Brain cortical organoids are an excellent model of human developing cortex. Using these analyses, we identified ATM-dependent phosphorylation predominantly influences factors in neurogenesis, neuronal differentiation, cell morphogenesis, and microtubule cytoskeleton as well as kinases involved in ATM, BNDF, and WNT signaling, G2/M checkpoint, and p53 regulation. These findings have broad implications about diseases associated with ATM, including ataxia telangiectasia.

2024-07-25 | PXD041699 | Pride

Integrated genomic and proteomic analyses identify stimulus-dependent molecular changes associated with distinct modes of skeletal muscle atrophy

Project description:Skeletal muscle atrophy is a debilitating condition that occurs with aging and disease but the underlying mechanisms are incompletely understood. Previous work determined that common transcriptional changes occur in muscle during atrophy induced by different stimuli. However, whether this holds true at the proteome level remains largely unexplored. Here, we find that, contrary to this earlier model, distinct atrophic stimuli (corticosteroids, cancer, and aging) induce largely different mRNA and protein changes during muscle atrophy in mice. Moreover, there is widespread transcriptome-proteome disconnect. Consequently, atrophy markers (atrogenes) identified in earlier microarray-based studies do not emerge from these proteomic surveys as the most relevantly associated with atrophy in all conditions. Rather, we identify proteins that are distinctly modulated by different types of atrophy (herein defined as “atroproteins”) such as the myokine CCN1/Cyr61, which regulates myofiber type switching during sarcopenia. Altogether, these integrated analyses indicate that different catabolic stimuli induce muscle atrophy via largely distinct mechanisms.

2022-02-22 | PXD027464 | Pride

Cross talks between mutant Leucine Rich Repeat Kinase 2 in the peripheral immune system and the CNS regulate neurodegeneration after environmental insult - part 1

Project description:Missense mutations in the Leucine Rich Repeat Kinase 2 (LRRK2) gene result in late-onset Parkinson’s disease (PD). The incomplete penetrance of LRRK2 mutations in humans and LRRK2 murine models of PD suggests that the disease may result from a complex interplay of genetic predispositions and persistent exogenous insults. To achieve a detailed characterization of the altered neuroinflammatory reaction in the brain of mutant LRRK2 mice, we performed mass spectrometry analysis (tandem mass tagging, TMT) of brain tissue obtained from intact and acute LPS-challenged WT and R1441G mutant mice.

2018-05-03 | PXD006290 | Pride

Human Neuron Proteome Altered by Disrupted in schizophrenia 1 (DISC1) Mutations

Project description:Disrupted in schizophrenia 1 is a protein that is encoded by the DISC1 gene in humans. In coordination with a wide array of interacting partners, DISC1 has been shown to participate in the regulation of cell proliferation, differentiation, migration, neuronal axon and dendrite outgrowth, synapse formation and maturation, synaptic transmission, mitochondrial transport, fission and/or fusion, and cell-to-cell adhesion. Several studies have shown that unregulated expression or altered protein structure of DISC1 may predispose individuals to the development of schizophrenia, major depression, bipolar disorder, and other psychiatric conditions. The cellular functions that are disrupted by permutations in DISC1, which lead to the development of these disorders, have yet to be clearly defined and are the subject of current ongoing research.

2021-09-08 | PXD013391 | Pride

Cross talks between mutant Leucine Rich Repeat Kinase 2 in the peripheral immune system and the CNS regulate neurodegeneration after environmental insult - part 2

Project description:Missense mutations in the Leucine Rich Repeat Kinase 2 (LRRK2) gene result in late-onset Parkinson’s disease (PD). The incomplete penetrance of LRRK2 mutations in humans and LRRK2 murine models of PD suggests that the disease may result from a complex interplay of genetic predispositions and persistent exogenous insults. To examine molecular pathways that might be affected by mutant LRRK2 in peripheral leukocytes, we performed mass spectrometry analysis (tandem mass tagging, TMT) on peripheral blood mononuclear cells obtained from intact and acute LPS-challenged WT and R1441G mutant mice.

2018-05-03 | PXD006289 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data